Cancer proteomics

Serum diagnostics for tumor marker discovery

Alex J. Rai, Daniel Wan-Yui Chan

Research output: Contribution to journalArticle

Abstract

Cancer proteomics is an exciting field that is witnessing many new developments in recent years. It is hoped that these advances will result in decreased cancer death rates, which have not declined dramatically in the last several decades. Some of the problems with current tumor markers include the lack of sensitivity and specificity, factors that prevent their use in population-based screening of disease. Thus, there is an urgent need to identify novel biomarkers that can faithfully detect the disease state. As we are now in the post-genome era, many opportunities have been created. Genomic sequence data are available for human, as well as several other species. We are now poised to mine these data and to determine the functions of the encoded proteins constituting the human genome. Proteomics affords this opportunity by providing enhanced procedures and tools for discovery and also a framework for understanding these components in terms of pathogenesis. New technologies and improvements in existing methodologies will allow for the rapid growth in the identification and characterization of peptides and proteins that are unique to various clinical states. This technology can be successfully applied to clinical specimens for the identification of new tumor markers.

Original languageEnglish (US)
Pages (from-to)286-294
Number of pages9
JournalAnnals of the New York Academy of Sciences
Volume1022
DOIs
StatePublished - 2004

Fingerprint

Tumor Biomarkers
Proteomics
Genes
Technology
Biomarkers
Human Genome
Serum
Neoplasms
Screening
Proteins
Genome
Sensitivity and Specificity
Peptides
Mortality
Growth
Population
Protein
Cancer
Diagnostics
Witnessing

Keywords

  • Cancer proteomics
  • Surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry
  • Tumor markers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cancer proteomics : Serum diagnostics for tumor marker discovery. / Rai, Alex J.; Chan, Daniel Wan-Yui.

In: Annals of the New York Academy of Sciences, Vol. 1022, 2004, p. 286-294.

Research output: Contribution to journalArticle

@article{469aa43570ae484c8dee82315aac6106,
title = "Cancer proteomics: Serum diagnostics for tumor marker discovery",
abstract = "Cancer proteomics is an exciting field that is witnessing many new developments in recent years. It is hoped that these advances will result in decreased cancer death rates, which have not declined dramatically in the last several decades. Some of the problems with current tumor markers include the lack of sensitivity and specificity, factors that prevent their use in population-based screening of disease. Thus, there is an urgent need to identify novel biomarkers that can faithfully detect the disease state. As we are now in the post-genome era, many opportunities have been created. Genomic sequence data are available for human, as well as several other species. We are now poised to mine these data and to determine the functions of the encoded proteins constituting the human genome. Proteomics affords this opportunity by providing enhanced procedures and tools for discovery and also a framework for understanding these components in terms of pathogenesis. New technologies and improvements in existing methodologies will allow for the rapid growth in the identification and characterization of peptides and proteins that are unique to various clinical states. This technology can be successfully applied to clinical specimens for the identification of new tumor markers.",
keywords = "Cancer proteomics, Surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry, Tumor markers",
author = "Rai, {Alex J.} and Chan, {Daniel Wan-Yui}",
year = "2004",
doi = "10.1196/annals.1318.044",
language = "English (US)",
volume = "1022",
pages = "286--294",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cancer proteomics

T2 - Serum diagnostics for tumor marker discovery

AU - Rai, Alex J.

AU - Chan, Daniel Wan-Yui

PY - 2004

Y1 - 2004

N2 - Cancer proteomics is an exciting field that is witnessing many new developments in recent years. It is hoped that these advances will result in decreased cancer death rates, which have not declined dramatically in the last several decades. Some of the problems with current tumor markers include the lack of sensitivity and specificity, factors that prevent their use in population-based screening of disease. Thus, there is an urgent need to identify novel biomarkers that can faithfully detect the disease state. As we are now in the post-genome era, many opportunities have been created. Genomic sequence data are available for human, as well as several other species. We are now poised to mine these data and to determine the functions of the encoded proteins constituting the human genome. Proteomics affords this opportunity by providing enhanced procedures and tools for discovery and also a framework for understanding these components in terms of pathogenesis. New technologies and improvements in existing methodologies will allow for the rapid growth in the identification and characterization of peptides and proteins that are unique to various clinical states. This technology can be successfully applied to clinical specimens for the identification of new tumor markers.

AB - Cancer proteomics is an exciting field that is witnessing many new developments in recent years. It is hoped that these advances will result in decreased cancer death rates, which have not declined dramatically in the last several decades. Some of the problems with current tumor markers include the lack of sensitivity and specificity, factors that prevent their use in population-based screening of disease. Thus, there is an urgent need to identify novel biomarkers that can faithfully detect the disease state. As we are now in the post-genome era, many opportunities have been created. Genomic sequence data are available for human, as well as several other species. We are now poised to mine these data and to determine the functions of the encoded proteins constituting the human genome. Proteomics affords this opportunity by providing enhanced procedures and tools for discovery and also a framework for understanding these components in terms of pathogenesis. New technologies and improvements in existing methodologies will allow for the rapid growth in the identification and characterization of peptides and proteins that are unique to various clinical states. This technology can be successfully applied to clinical specimens for the identification of new tumor markers.

KW - Cancer proteomics

KW - Surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=3242665953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242665953&partnerID=8YFLogxK

U2 - 10.1196/annals.1318.044

DO - 10.1196/annals.1318.044

M3 - Article

VL - 1022

SP - 286

EP - 294

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -